Chinese biotherapeutics platform Hangzhou Just Biotherapeutics (HJB) has secured a $35 million Series B+ round led by Beijing and Hong Kong-based private equity firm Hillhouse Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
